Table 4.
Selected clinical and laboratory features of patients 6 months after treatment.
| Parameters | Group 1 | Group 2 | Group 3 | Group 4 | P value |
|---|---|---|---|---|---|
| AST (IU/L) | 79.4 ± 10.08 | 86.0 ± 7.59 | 74.85 ± 8.92 | 82.85 ± 8.92 | 0.110 |
| ALT (IU/L) | 51.6 ± 8.06 | 51.9 ± 7.5 | 49.80 ± 10.49 | 56.8 ± 10.49 | 0.642 |
| BIL-T (mg/dL) | 2.40 ± 0.71 | 2.64 ± 0.64 | 2.47 ± 0.69 | 2.65 ± 0.61 | 0.767 |
| BIL-D (mg/dL) | 1.08 ± 0.35 | 1.16 ± 0.28 | 1.03 ± 0.25 | 1.28 ± 0.38 | 0.391 |
| Albumin (g/dL) | 2.71 ± 0.28 | 2.65 ± 0.25 | 2.67 ± 0.24 | 2.65 ± 0.21 | 0.012 |
| PT (sec.) | 30.9 ± 5.09 | 31.20 ± 5.25 | 30.7 ± 4.22 | 30.4 ± 2.07 | 0.886 |
| BUN (mg/dL) | 70.8 ± 13.77 | 72.9 ± 18.85 | 61.00 ± 9.03 | 72.7 ± 9.10 | 0.206 |
| s.Cr (mg/dL) | 1.68 ± 0.30 | 1.71 ± 0.39 | 0.99 ± 0.21 | 1.64 ± 0.47 | 0.001 |
| Sodium (mEq/L) | 128.4 ± 3.98 | 127.70 ± 4.64 | 126.60 ± 6.36 | 127.20 ± 3.79 | 0.994 |
| Hemoglobin (g/dL) | 8.80 ± 0.62 | 8.67 ± 0.48 | 10.28 ± 0.58 | 8.60 ± 0.47 | 0.001 |
| RBCs (106/uL) | 3.35 ± 0.2 | 3.22 ± 0.36 | 3.31 ± 0.34 | 3.26 ± 0.41 | 0.903 |
| WBCs (103/uL) | 7.45 ± 1.30 | 7.62 ± 0.91 | 7.26 ± 0.82 | 7.20 ± 0.88 | 0.926 |
| Platelets (103/uL) | 73.53 ± 9.45 | 73.261 ± 9.28 | 73.07 ± 9.70 | 73.44 ± 8.66 | 0.424 |
| TNF-α (pg/mL) | 84.27 ± 13.85 | 73.48 ± 7.27 | 91.19 ± 15.23 | 41.43 ± 7.07 | 0.000 |
Data presented by mean ± SD; AST: aspartate transaminase; ALT: alanine aminotransferase; BIL-T: total bilirubin; BIL-D: direct bilirubin; PT: prothrombin time; BUN: blood urea nitrogen; s.Cr: serum creatinine; RBCs: red blood cells; WBCs: white blood cells; TNF-α: tumor necrosis factor alpha; pg/mL: picograms per milliliter.